Evidence map›Paper›PMID 40873869›Full record

ArticleCentral European journal of urology2025

Differential prognostic impact of favourable prostate cancer pathology risk score patterns predicted by Briganti's 2012 nomogram across EAU risk groups: Analysis of 757 cases treated with robotic surgery.

Antonio Benito Porcaro, Sonia Costantino, Francesca Montanaro, Alberto Baielli, Francesco Artoni, Emanuele Serafin, Luca Roggero, Claudio Brancelli, Andrea Franceschini, Alessandro Princiotta and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Central European journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Antonio Benito PorcaroDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Sonia CostantinoDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Francesca MontanaroDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Alberto BaielliDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Francesco ArtoniDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Emanuele SerafinDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Luca RoggeroDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Claudio BrancelliDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Andrea FranceschiniDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Alessandro PrinciottaDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Michele BoldiniDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Lorenzo TreccaniDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Lorenzo De BonDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Alberto BianchiDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Alessandro VecciaDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Riccardo RizzettoDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Matteo BrunelliDepartment of Pathology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Vincenzo De MarcoDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Salvatore SiracusanoDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Maria Angela CerrutoDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Riccardo Giuseppe BertoloDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Alessandro AntonelliDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The aim of this study was to evaluate the prognostic impact of favourable prostate cancer (PCa) pathology patterns through Briganti's 2012 nomogram and beyond EAU risk classes in patients treated with robotic surgery. Material and methods: We analysed 757 patients from January 2013 to December 2021 with favourable pathology features (ISUP 1-3, pT2/pT3a, and pN0/x) and available follow-up. Pathologic features were scored from zero (ISUP 1 + pT2) to three (ISUP 3 + pT3a). Associations with Briganti's 2012 nomogram by EAU risk class were evaluated to determine the prognostic impact on PCa progression, defined as biochemical persistence/recurrence or loco-regional/metastatic recurrence. Results: Favourable pathology risk scores were most commonly grades one (49%) and two (30.95%), followed by zero (15.2%) and three (4.9%). After adjusting for EAU prognostic groups, higher nomogram scores were associated with increased risk scores of two and three. PCa progression occurred in 12.7% of cases after a mean follow-up of 92.1 months. Patients with recurrence had a worse prognosis as risk scores increased from one to three, even after adjustment for Briganti's 2012 nomogram by EAU class. Conclusions: Favourable pathology risk scores, grouped by Briganti's 2012 and EAU nomograms, impact prognosis. As scores increase, the likelihood of disease progression rises, potentially influencing treatment strategies.

Indexed as

EAU risk classesfavorable prostate cancer pathologyprostate cancerprostate cancer nomogramsprostate cancer progressionrobot assisted radical prostatectomy

Identifiers

PMID40873869
PMCPMC12379811

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.